Skip to main content

Pharmacokinetic

4
Pipeline Programs
7
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Inversago Pharma
Inversago PharmaQC - Montréal
1 program
1
INV-101Phase 1
Ascentage Pharma
Ascentage PharmaChina - Beijing
1 program
1
Olverembatinib 20mgPhase 11 trial
Active Trials
NCT07282093Recruiting48Est. Oct 2026
Quotient Therapeutics
Quotient TherapeuticsMA - Cambridge
1 program
1
PLENVU powder for oral solutionPhase 11 trial
Active Trials
NCT03437265Completed19Est. Oct 2020
Norgine
NorgineAustria - Vienna
1 program
1
PLENVU powder for oral solutionPhase 1
Chia Tai TianQing Pharmaceutical Group
2 programs
LanifibranorPHASE_11 trial
TQ-A3326PHASE_11 trial
Active Trials
NCT06126562Completed24Est. Dec 2023
NCT03714568Unknown60Est. Sep 2019
Gesynta Pharma
Gesynta PharmaSweden - Stockholm
1 program
Formulation A GS-248PHASE_11 trial
Active Trials
NCT04617509Completed14Est. May 2020
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
INV-101PHASE_11 trial
Active Trials
NCT04531150Completed40Est. May 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Ascentage PharmaOlverembatinib 20mg
Chia Tai TianQing Pharmaceutical GroupLanifibranor
Novo NordiskINV-101
Quotient TherapeuticsPLENVU powder for oral solution
Gesynta PharmaFormulation A GS-248
Chia Tai TianQing Pharmaceutical GroupTQ-A3326

Clinical Trials (6)

Total enrollment: 205 patients across 6 trials

NCT07282093Ascentage PharmaOlverembatinib 20mg

Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment

Start: Nov 2025Est. completion: Oct 202648 patients
Phase 1Recruiting

A Pharmacokinetic Study of Lanifibranor in Healthy Adult Chinese Subjects

Start: Oct 2023Est. completion: Dec 202324 patients
Phase 1Completed

Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects

Start: Sep 2020Est. completion: May 202140 patients
Phase 1Completed
NCT03437265Quotient TherapeuticsPLENVU powder for oral solution

A Pharmacokinetic Study of PLENVU® in Healthy Subjects

Start: Sep 2020Est. completion: Oct 202019 patients
Phase 1Completed
NCT04617509Gesynta PharmaFormulation A GS-248

A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248

Start: Mar 2020Est. completion: May 202014 patients
Phase 1Completed

Pharmacokinetic and Tolerance Study of TQ-A3326 in Healthy Participants.

Start: Nov 2018Est. completion: Sep 201960 patients
Phase 1Unknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 205 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.